The evolving role of checkpoint inhibitors in the treatment of Hodgkin lymphoma
Since their initial approval as single agent therapy for multiply relapsed/refractory Hodgkin lymphoma (HL), the PD-1 inhibitors nivolumab and pembrolizumab have been incorporated into second-line salvage regimens, and they are being investigated in upfront therapy of newly diagnosed patients. As se...
Na minha lista:
| Autor principal: | |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Frontiers Media S.A.
2024-10-01
|
| coleção: | Frontiers in Oncology |
| Assuntos: | |
| Acesso em linha: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1392653/full |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|